MiNK Therapeutics Email Format

Biotechnology ResearchMassachusetts, United States11-50 Employees

MiNK Therapeutics is a clinical-stage biopharmaceutical company based in Lexington, Massachusetts, focused on biotechnology research. It concentrates on the discovery, development, and commercialization of allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies to treat cancer and immune-mediated diseases. iNKT cells are described as a distinct T cell population with durable memory responses and rapid cytolytic features, offering potential advantages for allogeneic therapy such as tissue homing, clearance of tumors and infected cells, and suppression of graft-versus-host disease. The company operates a proprietary platform designed to enable scalable, reproducible manufacturing for off-the-shelf delivery and maintains a wholly owned pipeline of native and engineered iNKT cell products. It pursues collaborations to advance targeted therapies, including PRAME-targeted TCR-engineered iNKT cell therapy for pediatric cancers with partners such as C-Further and the University of Southampton.

Sign up for free to view info

Company overview Employee directory